Yiqi Huoxue decoction inhibits malignant biological behavior of human lung cancer cells via the miR-21/PTEN signaling pathway

doi:10.12092/j.issn.1009-2501.2020.05.005

Abstract

Abstract: AIM: To investigate the inhibitory effect of Yiqi Huoxue decoction on the malignant biological behavior of lung cancer cells and its mechanism. METHODS: Human lung cancer A549 cells were treated with different doses of Yiqi Huoxue Decoction serum (5%, 10%, 15%). CCK-8 assay, transwell chamber experiment, flow cytometry, Western blot and qRT-PCR method were used to study the effect of different doses of Yiqi Huoxue Decoction-containing serum to cell proliferation, cell migration and invasion, cell apoptosis, PTEN protein and miR-21 expression. RESULTS: Compared with the drug-free serum group, survival rate, migration and invasion ability of A549 cells decreased after treatment with different doses of drug-containing serum. The apoptosis rate of A549 cells increased, PTEN mRNA and the expression of its protein increased, the expression of miR-21 decreased, and the medium-dose (10%) drug-containing serum group had the best effect. After the transfection of miR-21 mimics, miR-21 expression was up-regulated, while PTEN protein expression was down-regulated in cells. PTEN protein expression was up-regulated after treatment with medium-dose (10%) drug-containing serum. CONCLUSION: Yiqi Huoxue Decoction can effectively inhibit the malignant cell biological behavior of human lung cancer A549 cells and may be related to the regulation of the miR-21/PTEN signaling pathway.

Key words: Yiqi Huoxue decoction, miR-21/PTEN signaling pathway, lung cancer cells, malignant biological behavior, inhibitory effect, mechanism

CLC Number:

R965.2

YANG Guoliang, HU Dandan, XU Yikai, LOU Liming. Yiqi Huoxue decoction inhibits malignant biological behavior of human lung cancer cells via the miR-21/PTEN signaling pathway[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(5): 512-518.

References

[1]Liu TC, Jin X, Wang Y, et al. Role of epidermal growth factor receptor in lung cancer and targeted therapies [J]. Am J Cancer Res, 2017, 7(2): 187-202.
[2]Zhang Y. Chemotherapy in advanced non-small cell lung cancer: present and future [J]. J Int Transl Med, 2017, 5(1): 38-44.
[3]Chen M. Clinical efficacy of thymopentin combined with chemotherapy on non-small cell lung cancer patients and the impact on CD, NK cells [J]. Clin Med, 2017, 4(1): 120-129.
[4]Xu G, Shao G, Pan Q, et al. MicroRNA-9 regulates non-small cell lung cancer cell invasion and migration by targeting eukaryotic translation initiation factor 5A2 [J]. Am J Transl Med, 2017, 9(2): 478-488.
[5]Qi Z, Zhang B, Zhang J, et al. MicroRNA-30b inhibits non-small cell lung cancer cell growth by targeting the epidermal growth factor receptor [J]. Neoplasma, 2018, 65(2): 192-200.
[6]Gong XF, Yu AL, Tang J, et al. MicroRNA-630 inhibits breast cancer progression by directly targeting BMI1 [J]. Exp Cell Res, 2018, 362(2): 378-385.
[7]Liu C, Liu RF, Zhang DX, et al. MicroRNA-141 suppresses prostate cancer stem cells and metastasis by targeting a cohort of pro-metastasis genes including CD44, Rho GTPases, and EZH2 [J]. Nat Commun, 2017, 23(8): 14270-14282.
[8]Li GC, Cao XY, Li YN, et al. MicroRNA‐374b inhibits cervical cancer cell proliferation and induces apoptosis through the p38/ERK signaling pathway by binding to JAM‐2 [J]. J Cell Physiol, 2018, 233(9): 7379-7390.
[9]Feng Y, Deng C, Hu C, et al. Modulation of CASC2/miR-21/PTEN pathway sensitizes cervical cancer to cisplatin [J]. Arch Biochem Biophys, 2017, 1(1): 20-30.
[10]Kao HW, Pan CY, Lai CH, et al. Urine miR-21-5p as a potential non-invasive biomarker for gastric cancer [J]. Oncotarget, 2018, 9(34): 56389-56397.
[11]Zhang JY, a J, Yu P, et al. Reduced beta 2 glycoprotein I prevents high glucose-induced cell death in HUVECs through miR-21/PTEN [J]. Am J Transl Res, 2017, 9(9): 3935-3949.
[12]Hao XJ, Xu CZ, Wang JT P, et al. miR-21 promotes proliferation and inhibits apoptosis of hepatic stellate cells through targeting PTEN/PI3K/AKT pathway [J]. J Recept Signal Transduct Res, 2018, 38(5): 455-461.
[13]王佳. 281例非小细胞肺癌患者血脂水平及凝血功能相关性的临床观察 [D]. 中国中医科学院, 2017.
[14]黄清旭. 益气活血汤治疗血栓性浅静脉炎62例 [J]. 实用中医药杂志, 2018, 7(7): 781-782.
[15]林小亮, 陈少荣. 益气活血汤联合乌司他丁治疗充血性心力衰竭疗效及对相关细胞因子的影响 [J]. 现代中西医结合杂志, 2016, 25(1): 2779-2781.
[16]柳根哲, 孙旗, 陈江, 等. 高静水压下益气活血汤通过p38MAPK信号通路对兔椎体终板软骨细胞的调控作用 [J]. 现代中西医结合杂志, 2018, 10(1): 1027-1030.
[17]Cao Z, Chen L. Inhibition of miR-27a suppresses the inflammatory response via the p38/MAPK pathway in intervertebral disc cells [J]. Exp Ther Med, 2017, 14(5): 4572-4578.
[18]李铁英, 李华, 战涛. 不可逆性泛HER抑制剂HM781-36B在埃罗替尼耐药型非小细胞肺癌中的抗肿瘤活性 [J]. 安徽医学, 2016, 38(1): 29-32.
[19]Huo X, Zhang L, Li T. Analysis of the association of the expression of KiSS-1 in colorectal cancer tissues with the pathology and prognosis [J]. Omcol Lett, 2018, 15(3): 3056-3060.
[20]Yu YX, Wang Y, Liu H. Overexpression of PTEN suppresses non-small-cell lung carcinoma metastasis through inhibition of integrin αVβ6 signaling [J]. Am J Transl Res, 2017, 9(7): 3304-3314.
[21]Fumarola C, Cretella D, Monica SL, et al. Enhancement of the anti-tumor activity of FGFR1 inhibition in squamous cell lung cancer by targeting downstream signaling involved in glucose metabolism [J]. Oncotarget, 2017, 8(54): 91841-91859.
[22]赵文, 马骏, 王志晓. 龙葵中抗肿瘤活性成分及其作用研究进展 [J]. 中兽医医药杂志, 2019, 3(1): 23-25.
[23]王萍, 石海莲, 吴晓俊. 中药草豆蔻抗肿瘤化学成分和作用机制研究进展 [J]. 中国药理学与毒理学杂志, 2017, 9(1): 880-888.
[24]来慧丽, 吴文如, 陈侠, 等. 岭南中药广藿香活性成分诱导肿瘤细胞凋亡的研究进展 [J]. 中国中医药现代远程教育, 2019, 17(16): 134-136.
[25]Li RK, Gao J, Guo LH, et al. PTENP1 acts as a ceRNA to regulate PTEN by sponging miR-19b and explores the biological role of PTENP1 in breast cancer [J]. Cancer Gene Ther, 2017, 24(7): 309-315.
[26]Ye L, Wang Y, Nie L, et al. MiR-130 exerts tumor suppressive function on the tumorigenesis of human non-small cell lung cancer by targeting PTEN [J]. Am J Transl Res, 2017, 9(4): 1856-1865.
[27]Vasuri F, Fittipaldi S, Pace VD,et al.Tissue miRNA 483-3p expression predicts tumor recurrence after surgical resection in histologically advanced hepatocellular carcinomas [J]. Oncotarget, 2018, 9(25): 17895-17905.
[28]Xu S, Shi L. High expression of miR-155 and miR-21 in the recurrence or metastasis of non-small cell lung cancer [J]. Oncol Lett, 2019, 18(1): 758-763.